Wed, April 20, 2022
Tue, April 19, 2022
Mon, April 18, 2022
Sun, April 17, 2022
Thu, April 14, 2022
Wed, April 13, 2022
Tue, April 12, 2022

Colin Bristow Maintained (CCCC) at Strong Buy with Decreased Target to $26 on, Apr 18th, 2022


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. ith-decreased-target-to-26-on-apr-18th-2022.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Colin Bristow of UBS, Maintained "C4 Therapeutics, Inc." (CCCC) at Strong Buy with Decreased Target from $64 to $26 on, Apr 18th, 2022.

Colin has made no other calls on CCCC in the last 4 months.



There are 3 other peers that have a rating on CCCC. Out of the 3 peers that are also analyzing CCCC, 1 agrees with Colin's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Derek Archila of "Wells Fargo" Initiated at Hold and Held Target at $25 on, Thursday, February 10th, 2022


These are the ratings of the 2 analyists that currently disagree with Colin


  • Etzer Darout of "BMO Capital" Maintained at Buy with Decreased Target to $20 on, Monday, April 11th, 2022
  • Eric Joseph of "JP Morgan" Initiated at Buy and Held Target at $43 on, Thursday, March 10th, 2022

Publication Contributing Sources